CytomX Therapeutics Inc

CytomX Therapeutics Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009 an antibody drug conjugates (ADC) against CD166 which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer head and neck squamous cell carcinoma esophageal and gastro-esophageal junction cancers and diffuse large B-cell lymphoma; CX-2051 a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801 a dually masked conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288 an anti-CTLA-4 Probody drug which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904 a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company Amgen Inc. Bristol-Myers Squibb Company Astellas Pharma Inc. ModernaTX Inc. and Regeneron Pharmaceuticals Inc. The company was founded in 2008 and is headquartered in South San Francisco California.